Requirements for Th1-dependent immunity against infection with Leishmania major

Microbes and Infection

Volumn 6, Issue 12, 2004, Pages 1102-1109

  Von Stebut, Esther ^a   Udey, Mark C ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dendritic cells; IL 12; Leishmania; Macrophages; Th1

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; DAPSONE; INTERLEUKIN 1; INTERLEUKIN 12; ITRACONAZOLE; LEISHMANIA VACCINE; MEGLUMINE ANTIMONATE; PAROMOMYCIN; RIFAMPICIN; STIBOGLUCONATE SODIUM;

ANTIGEN PRESENTING CELL; CELL FUNCTION; CELL MATURATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE MODEL; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; HEALTH CARE PLANNING; HUMAN; IMMUNITY; INFECTION RESISTANCE; INOCULATION; LEISHMANIA MAJOR; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SKIN LEISHMANIASIS; TH1 CELL; TH2 CELL;

LEISHMANIA MAJOR; MURINAE;

EID: 4544328132     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micinf.2004.05.024     Document Type: Short Survey

References (45)

1. Melby P.C. Experimental leishmaniasis in humans: Review Rev. Infect. Dis. 13 1991 1009 1017
2. Scott P., and Farrell J.P. Experimental cutaneous leishmaniasis: Induction and regulation of T cells following infection of mice with Leishmania major Chem. Immunol. 70 1998 60 80
3. Belkaid Y., Mendez S., Lira R., Kadami N., Milon G., and Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity J. Immunol. 165 2000 969 977
4. Sacks D., and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice Nat. Rev. Immunol. 2 2002 845 858
5. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major J. Immunol. 168 2002 3992 4000
6. Bogdan C., Rollinghoff M., and Diefenbach A. The role of nitric oxide in innate immunity Immunol. Rev. 173 2000 17 26
7. Mitchell G.F., Curtis J.M., and Handman E. Resistance to cutaneous leishmaniasis in genetically susceptible BALB/c mice Aust. J. Exp. Biol. Med. Sci. 59 1981 555 565
8. Beebe A.M., Mauze S., Schork N.J., and Coffman R.L. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice Immunity 6 1997 551 557
9. Blackwell J.M. Genetic susceptibility to leishmanial infections: Studies in mice and man Parasitology 112 1996 S67 S74
10. Bottrel R.L., Dutra W.O., Martins F.A., Gontijo B., Carvalho E., Barral-Neto M., Barral A., Almeida R.P., Mayrink W., Locksley R., and Gollob K.J. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis Infect. Immun. 69 2001 3232 3239
11. Bourreau E., Gardon J., Pradinaud R., Pascalis H., Prevot-Linguet G., Kariminia A., and Pascal L. The responses predominate during the early phases of infection in patients with localized cutaneous leishmaniasis and precede the development of Th1 responses Infect. Immun. 71 2003 2244 2246
12. Rogers K.A., DeKrey G.K., Mbow M.L., Gillespie R.D., Brodskyn C.I., and Titus R.G. Type 1 and type 2 responses to Leishmania major FEMS Microbiol. Lett. 209 2002 1 7
13. Kolde G., Luger T., Sorg C., and Sunderkötter C. Successful treatment of cutaneous leishmaniasis using interferon-gamma Dermatology 192 1996 56 60
14. Modlin R.L. Th1-Th2 paradigm: insights from leprosy J. Invest. Dermatol. 102 1994 828 832
15. Carrera L., Gazzinelli R.T., Badolato R., Hieny S., Muller W., Kuhn R., and Sacks D.L. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice J. Exp. Med. 183 1996 515 526
16. Moll H., Fuchs H., Blank C., and Rollinghoff M. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells Eur. J. Immunol. 23 1993 1595 1601
17. von Stebut E., Belkaid Y., Jakob T., Sacks D.L., and Udey M.C. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity J. Exp. Med. 188 1998 1547 1552
18. von Stebut E., Belkaid Y., Nguyen B.V., Cushing M., Sacks D.L., and Udey M.C. Leishmania major-infected murine Langerhans cells-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous leishmaniasis Eur. J. Immunol. 30 2000 3498 3506
19. Flohe S.B., Bauer C., Flohe S., and Moll H. Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major Eur. J. Immunol. 28 1998 3800 3811
20. Reis e Sousa C., Stahl P.D., and Austyn J.M. Phagocytosis of antigens by Langerhans cells in vitro J. Exp. Med. 178 1993 509 519
21. + T cell polarization in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells J. Exp. Med. 198 2003 201 209
22. Mattner F., Di Padova K., and Alber G. Interleukin-12 is indispensable for protective immunity against Leishmania major Infect. Immun. 65 1997 4378 4383
23. Reis e Sousa C., Hieny S., Scharton-Kersten T., Jankovic D., Charest H., Germain R.N., and Sher A. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas J. Exp. Med. 186 1997 1819 1829
24. Scott P. Development and regulation of cell-mediated immunity in experimental leishmaniasis Immunol. Res. 27 2003 489 498
25. Moll H., Flohe S., and Blank C. Dendritic cells seclude Leishmania parasites that persist in cured mice - a role in the maintenance of T-cell memory? Adv. Exp. Med. Biol. 378 1995 507 509
26. Belkaid Y., Hoffmann K.F., Mendez S., Kamhawi S., Udey M.C., Wynn T.A., and Sacks D.L. The role of interleukin 10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure J. Exp. Med. 194 2001 1497 1506
27. + regulatory T cells control Leishmania major persistence and immunity Nature 420 2002 502 507
28. Shankar A.H., and Titus R.G. T cell and non-T cell compartments can independently determine resistance to Leishmania major J. Exp. Med. 181 1995 845 855
29. Reiner R.L., and Locksley R.M. The regulation of immunity to Leishmania major Annu. Rev. Immunol. 13 1995 151 177
30. + T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10-/- setting Immunity 16 2002 429 439
31. von Stebut E., Ehrchen J.M., Belkaid Y., Kostka S.L., Molle K., Knop J., Suderkotter C., and Udey M.C. Interleukin 1-alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice J. Exp. Med. 198 2003 191 199
32. Shibuya K., Robinson D., Zonin F., Hartley S.B., Macatonia S.E., Somoza C., Hunter C.A., Murphy K.M., and O'Garra A. IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice J. Immunol. 160 1998 1708 1716
33. Holscher C. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases Med. Microbiol. Immunol. (Berl) 193 2004 1 17
34. Monteforte G.M., Takeda K., Rodriguez-Sosa M., Akira S., David J.R., and Satoskar A.R. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection J. Immunol. 164 2000 5890 5893
35. +, and CD4- CD8- T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18 J. Immunol. 160 1998 3759 3765
36. Robinson D.S., and O'Garra A. Further checkpoints in Th1 development Immunity 16 2002 755 758
37. Mattner F., Magram J., Ferrante J., Launois P., Di Padova K., Behin R., Gately M.K., Louis J.A., and Alber G. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response Eur. J. Immunol. 26 1996 1553 1559
38. Yoshida H., Hamano S., Senaldi G., Covey T., Faggioni R., Mu S., Xia M., Wakeham A.C., Nishina H., Potter J., Saris C.J., and Mak T.W. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection Immunity 15 2001 569 578
39. Artis D., Johnson L.M., Joyce K., Saris C., Villarino A., Hunter C.A., and Scott P. Cutting Edge: Early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection J. Immunol. 172 2004 4672 4675
40. Nieuwenhuis E.E., Neurath M.F., Corazza N., Iijima H., Trgovcich J., Wirtz S., Glickman J., Bailey D., Yoshida M., Galle P.R., Kronenberg M., Birkenbach M., and Blumberg R.S. Disruption of T helper 2-immune responses in Epstein-Barr virus-induced gene 3-deficient mice Proc. Natl. Acad. Sci. USA 99 2002 16951 16956
41. Faghihi G., and Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate Clin. Exp. Dermatol. 28 2003 13 16
42. Moll H. Dendritic cells as a tool to combat infectious diseases Immunol. Lett. 85 2003 153 157
43. Berberich C., Ramirez-Pineda J.R., Hambrecht C., Alber G., Skeiky Y.A., and Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens J. Immunol. 170 2003 3171 3179
44. Ahuja S.S., Reddick R.L., Sato N., Montalbo E., Kostecki V., Zhao W., Dolan M.J., Melby P.C., and Ahuja S.K. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection J. Immunol. 163 1999 3890 3897
45. Brodskyn C., De Oliveira C.I., Barral A., and Barral-Netto M. Vaccine in leishmaniasis: Advances in the last five years Expert Rev. Vaccines 2 2003 705 717